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 Numerous factors contribute to maintain-
ing elevated parathyroid hormone (PTH) 
levels in patients with advanced renal fail-
ure. Th rough a variety of cellular mecha-
nisms, hypocalcemia, hyperphosphatemia, 
nutritional vitamin D deficiency, and 
calcitriol deficiency increase either 
parathyroid gland mass, secretion of PTH, 
or both ( Figure 1a ). Although the litera-
ture abounds with elegant diagrams that 
demonstrate the complex interactions 
between the main pathophysiological fac-
tors in disordered mineral metabolism in 
chronic kidney disease (CKD), a most 
basic, almost naive question has gone 
largely unanswered: where does it all 
begin? Is an increased PTH level in 
response to hypocalcemia or phosphate 
retention or calcitriol defi ciency the key 
initiating factor in disordered mineral 
metabolism in CKD, or is the primary 
driving force increased circulating 
concentrations of fi broblast growth factor 
23 (FGF23), the recently discovered 
phosphate — and vitamin D — regulating 
hormone? Th is nephrology version of the 
chicken-or-the-egg conundrum is the 
subject of the report by Hasegawa  et al. 1 
in this issue of  Kidney International . 
 The investigators induced chronic 
glomerulonephritis in rats by injecting 
antiglomerular basement membrane anti-
bodies in order to study the sequence of 
pathophysiological events underlying 
disordered mineral metabolism in early 
and progressive CKD. In a further step, 
they report the fi rst application of neutral-
izing anti-FGF23 antibodies in an  in vivo 
CKD model. Th ey used the antibodies as 
a physiological probe to further dissect 
the relative contributions of PTH and 
FGF23 in early CKD. 
 Over the fi rst 4 weeks aft er the develop-
ment of nephritis, serum creatinine nearly 
doubled, but there was no diff erence in 
serum phosphate levels as compared with 
the control animals. Th e nephritic animals 
maintained normal serum phosphate con-
centrations, despite consuming standard 
1 % phosphorus chow, by increasing their 
urinary fractional excretion of phosphate 
by 65 % . Indeed, the only nonsignifi cant 
biochemical diff erence between the CKD 
and control rats aft er 4 weeks was their 
serum phosphate level. By then, the rats 
with CKD had significantly increased 
FGF23 and PTH levels and reduced calci-
triol and (modestly) calcium levels, all of 
which characterize human CKD. 
 A closer look at the fi rst few weeks aft er 
CKD was induced revealed the fi rst set of 
novel fi ndings reported in this study. A 
signifi cant increase in FGF23 levels was 
already detectable in the CKD rats as com-
pared with the normal rats 10 days aft er 
the antiglomerular basement antibodies 
were administered, which was when 
follow-up blood was fi rst sampled. Impor-
tantly, creatinine had increased only 
subtly at that point, and serum phosphate 
was unchanged. Only later, on day 20, did 
the reduction in calcitriol levels and the 
increase in PTH achieve statistical sig-
nifi cance. Serum phosphate levels fi nally 
rose on day 30 after more severe renal 
dysfunction developed. Consistent with 
the known eff ects of FGF23 on vitamin D 
metabolism, and contrary to those of 
PTH, the animals with CKD demon-
strated a 50 % reduction in 1-  -hydroxy-
lase expression and a fi vefold increase in 
24-hydroxylase expression as compared 
with the control animals. Collectively, 
these results provide direct experimental 
evidence in favor of the conceptual frame-
work of the primacy of increased FGF23 
in the pathogenesis of secondary hyper-
parathyroidism that was proposed by 
clinical investigators studying patients 
with early CKD 2,3 and supported by stud-
ies of mice engineered to overexpress 
FGF23 (ref.  4 ) ( Figure 1b ). 
 Th is construct was confi rmed by the 
second set of novel results, which 
described the eff ects of treatment with 
anti-FGF23 antibodies. Within 24  h of 
administering the neutralizing antibodies, 
urinary fractional excretion of phosphate 
decreased and serum phosphate levels 
rose to an extent commensurate with the 
dose of antibody. Eliminating the eff ect of 
FGF23 with neutralizing antibody mark-
edly increased expression of 1-  -hydro-
xylase and decreased expression of 
24-hydroxylase within 8  h of injection. As 
a result, calcitriol levels increased signifi -
cantly and in fact were completely 
normalized relative to the control animals. 
Th is critical fi nding defi nitively confi rms 
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that increased FGF23 is the mechanism of 
reduced calcitriol levels in early CKD and 
discredits the view that insuffi  cient renal 
mass is an important early contributor. 
Furthermore, the concept that abolishing 
FGF23 action can normalize calcitriol lev-
els suggests that clinical strategies that 
reduce FGF23 might be a signifi cant step 
forward from our current reactive clinical 
management, which emphasizes treat-
ment with vitamin D aft er PTH is already 
elevated, toward a proactive strategy 
of primary prevention of secondary 
hyperparathyroidism itself. 
 In addition to the study ’ s strengths, its 
limitations should also be noted. While 
Hasegawa  et al. 1 establish the sequence of 
pathophysiological events in animals with 
progressive glomerulonephritis, it is likely 
that there are multiple avenues to second-
ary hyperparathyroidism in humans. 
Th ese could diff er by etiology of kidney 
disease, and separate factors such as nutri-
tional vitamin D defi ciency could drive 
increased PTH secretion independent of 
and before the rise in FGF23. Moreover, 
although the model closely resembles the 
biochemical phenotype in patients with 
early CKD, the mechanism of the subtle 
but signifi cant decrease in serum calcium 
levels that coincided with the increase in 
FGF23 on day 10 is not clear. Additional 
blood and urine samplings between days 
0 and 10 might have been instructive. 
 Th e fi ndings of Hasegawa  et al. 1 help 
extend our understanding of the patho-
genesis of disordered mineral metabolism 
one step upstream from calcitriol defi -
ciency to FGF23 excess but they also beget 
the next logical question: what stimulates 
the early elevation of FGF23 in CKD? It is 
unlikely that phosphate  ‘ retention ’ could 
explain increased FGF23 as early as 10 
days aft er the kidney was injured when, if 
anything, there was a modest  decrease in 
serum phosphate levels in the CKD rats. 
Although this is unproven, we can specu-
late that injury or disease of the kidney 
itself might raise FGF23 levels directly, 
even without a reduction in glomerular 
filtration rate. Studies of patients with 
known kidney disease but preserved 
glomerular fi ltration rate, such as certain 
forms of nephrotic syndrome or early 
stages of adult polycystic kidney disease, 
could be performed to test this hypothesis. 
A primary reduction of klotho expression 
has been proposed as a mechanism of 
FGF23 resistance that could stimulate 
increased FGF23 secretion. 5 However, this 
is unproven, and the reverse is equally 
plausible. Chronically elevated FGF23 
levels in CKD could be the primary factor 
that decreases klotho expression, as was 
demonstrated in FGF23 transgenic mice. 6 
Finally, there could be other upstream 
factors, such as changes in bone metabo-
lism, that might stimulate early increases 
in FGF23 secretion. Investigators should 
continue to focus on unraveling the 
regulation of FGF23 secretion in CKD. 
 In the meantime, the report by Hasegawa 
 et al. 1 has diagnostic and therapeutic 
implications. Th ese results indicate that 
increased FGF23 is probably the most 
sensitive biomarker of disordered phos-
phorus metabolism in early CKD and 
certainly more sensitive than hyperphos-
phatemia. If interventions that lower 
FGF23 are shown to improve patient 
outcomes, screening FGF23 levels in CKD 
patients could soon be integrated into 
clinical practice. From a therapeutic 
perspective, targeting dietary phosphorus 
absorption has been the primary focus of 
FGF23-lowering strategies. 7 Th e current 
study suggests a novel paradigm of directly 
blocking the eff ects of FGF23 using mono-
clonal antibodies. Th is strategy might be 
justifi ed if FGF23 excess is found to be a 
direct mediator of renal and cardiovascu-
lar toxicity related to disordered phospho-
rus metabolism rather than just a sensitive 
biomarker of it. If so, blocking FGF23 
could be particularly attractive for dialysis 
patients, in whom FGF23 excess is 
strongly associated with mortality, 8 but it 
plays a smaller role in regulating serum 
phosphate because of lack of renal func-
tion. Although the risk of inducing severe 
hyperphosphatemia would likely preclude 
the use of anti-FGF23 antibodies in pre-
dialysis patients who rely on FGF23 to 
augment urinary phosphate excretion, a 
subtle component of the data presented by 
Hasegawa  et al. , 1 on which the authors did 
not comment, suggests a potential thera-
peutic opportunity even in predialysis 
patients. Although the lower dose (0.1  mg / kg) 
of anti-FGF23 antibody resulted in com-
plete restoration of calcitriol levels, 
comparable to the eff ect of the higher dose 
(1.0  mg / kg), the lower dose raised serum 
phosphate only modestly compared with 
the sharp increase caused by the higher 
dose. Whether the diff erential eff ects on 
phosphate handling versus calcitriol 
production could be further dissociated 
 Figure 1  |  Pathogenesis of disordered mineral metabolism in CKD. ( a ) Traditional view of the 
mechanisms that maintain secondary hyperparathyroidism in advanced chronic kidney disease. 
( b ) Updated view of the mechanisms that initiate secondary hyperparathyroidism in chronic 
kidney disease, emphasizing the central role of FGF23. CaR, calcium sensing receptor; FGFR, 
fibroblast growth factor receptor; PTH, parathyroid hormone; VDR, vitamin D receptor. 
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to minimize the risk of hyperphos-
phatemia is interesting but would require 
extensive study. Establishing whether anti-
FGF23 antibodies have a clinical role in 
CKD is one of many next logical steps in 
the ongoing, comprehensive development 
plan of FGF23 for clinical practice. 
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 Specialized cells along the collecting 
duct —  - and   -intercalated cells — carry 
out acid or base secretion. The   - and 
  -intercalated cells are functional mirror 
images of one another. Th e   -intercalated 
cell mediates H   +   secretion and the 
  -intercalated cell HCO 3   −   secretion. Acid /
 base secretion in these cells is driven by an 
active pump, the vacuolar H   +   -ATPase, 
inserted into one plasma membrane 
domain, and there is a passive, base 
exit step, a Cl   −   / HCO 3   −   exchanger, in 
the opposite membrane domain. The 
 Adaptation of intercalated cells 
along the collecting duct to 
systemic acid / base changes 
 John H.  Schwartz 1 and  Edward A.  Alexander 1 
 Collecting duct intercalated cells respond to short-term acid / base 
perturbations by rapidly shuttling H   +   -ATPase to and from the plasma 
membrane. Purkerson  et al. provide information on the regulation of the 
anion transporters during chronic acidosis and acute recovery 
(alkalosis). They found that the major mechanism for both acute and 
chronic states is regulation of both the H   +   -ATPase and the anion 
exchangers plus changes in the overall expression level of these anion 
transporters in chronic adaptation. 
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  -intercalated cell has its vacuolar H   +   -
ATPase inserted into the apical membrane 
and an anion exchanger, AE1, inserted into 
the basolateral membrane. In contrast, in 
  -intercalated cells, the H   +   -ATPase is 
inserted into the basolateral domain, and 
pendrin is the anion exchanger inserted 
into the apical membrane of these cells. 
 Regulation of net acid / base transport by 
collecting duct intercalated cells, induced 
by systemic acid / base changes, is moder-
ated by both short-term (minutes) and 
long-term (hours to days) processes. 1 
It has been widely accepted that short-
term acid / base regulation is achieved pri-
marily by exocytic insertion of sub-plasma 
membrane H   +   -ATPase-coated vesicles 
into the plasma membrane and down-
regulation by endocytic retrieval of the 
H   +   -ATPase back into the sub-membrane 
vesicular pool in both   - and   -interca-
lated cells ( Figure 1 ). 1 Th e signal cascade 
and molecular mechanism for acidosis-
induced exocytic insertion of the H   +   -
ATPase into the apical membrane of 
  -intercalated cells has been characterized 
in some detail. 2 Fusion of these vesicles is 
SNARE dependent. Apical membrane syn-
taxin-1 and SNAP23 form complexes with 
VAMP-2 that is localized on the surface of 
H   +   -ATPase-coated vesicles. Th is SNARE 
fusion complex, along with  N -ethylmale-
imide-sensitive factor (NSF), induces the 
fusion of the vesicle with the apical mem-
brane. Th e signal cascade that activates 
exocytosis in   -intercalated cells is initiated 
by a fall in cell pH and rise in cell calcium. 3 
Recent evidence also points to a role for 
HCO 3   −   -sensitive, soluble adenylate cyclase 
in the signal cascade. 4 Th e information for 
targeting of the H   +   -ATPase-coated vesicle 
to the appropriate membrane (apical and /
 or basolateral domains) is in part contained 
within the H   +   -ATPase itself. 5 
 Less attention has been paid to regula-
tion by changes in the systemic acid / base 
status of the passive HCO 3   −   exit step across 
the basolateral membrane of   -interca-
lated cells or the apical membrane of   -
intercalated cells. Although systemic 
acidosis induces increased basolateral 
expression of AE1 in   -intercalated cells 
and alkalosis increases expression of api-
cal membrane pendrin in   -intercalated 
cells, the mechanism for and kinetics of 
these changes have not been elucidated. 6,7 
